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Giardia intestinalis is a microaerophilic protozoan that is an important etiologic agent of diarrhea worldwide. There is evidence
that under diverse conditions, the parasite is capable of shedding extracellular vesicles (EVs) which modulate the physiopathology
of giardiasis. Here we describe new features of G. intestinalis EV production, revealing its capacity to shed two different enriched
EV populations: large (LEV) and small extracellular vesicles (SEV) and identified relevant adhesion functions associated with the
larger population. Proteomic analysis revealed differences in proteins relevant for virulence and host-pathogen interactions
between the two EV subsets. We assessed the effect of two recently identified inhibitors of EV release in mammalian cells, namely
peptidylarginine deiminase (PAD) inhibitor and cannabidiol (CBD), on EV release from Giardia and their putative effects on
host-pathogen interactions. PAD-inhibitor Cl-amidine and CBD were both able to effectively reduce EV shedding, the PAD-inhibitor
specifically affecting the release of LEVs and reducing parasite attachment to host cells in vitro. The strong efficacy of the
PAD-inhibitor on Giardia EV release indicates a phylogenetically conserved pathway of PAD-mediated EV release, most likely
affecting the Giardia arginine deiminase (GiADI) homolog of mammalian PADs. Our results suggest that LEVs and SEVs are
differently involved in protozoa communication, and that treatment with EV-inhibitors may be a novel strategy for recurrent
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28 Abstract
29 Giardia intestinalis is a microaerophilic protozoan that is an important etiologic agent of
30 diarrhea worldwide. There is evidence that under diverse conditions, the parasite is
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31 capable of shedding extracellular vesicles (EVs) which modulate the physiopathology of
32 giardiasis. Here we describe new features of G. intestinalis EV production, revealing its
33 capacity to shed two different enriched EV populations: large (LEV) and small
34 extracellular vesicles (SEV) and identified relevant adhesion functions associated with
35 the larger population. Proteomic analysis revealed differences in proteins relevant for
36 virulence and host-pathogen interactions between the two EV subsets, such as
37 cytoskeletal and anti-oxidative stress response proteins in LEVS We assessed the effect
38 of two recently identified inhibitors of EV release in mammalian cells, namely
39 peptidylarginine deiminase (PAD) inhibitor and cannabidiol (CBD), on EV release from
40 Giardia. The compounds were both able to effectively reduce EV shedding, the PAD-
41 inhibitor specifically affecting the release of LEVs and reducing parasite attachment to
42 host cells in vitro.. Our results suggest that LEVs and SEVs have a different role in host-
43 pathogen interaction, and that treatment with EV-inhibitors may be a novel treatment
44 strategy for recurrent giardiasis.
45
46 Keywords: Host-pathogen interaction; Extracellular vesicles; Giardia intestinalis;
47 Peptidylarginine deiminase inhibitor, Cannabidiol (CBD)
48
49
50
51 Introduction
52 Giardia intestinalis is a lumen dwelling pathogen in the vertebrate gut which is
53 responsible for a worldwide waterborne diarrhea known as giardiasis. It affects millions
54 of people worldwide and remains a neglected disease (Savioli et al., 2006; reviewed by
55 Ankarklev et al., 2010; Cernikova et al., 2018). The life cycle of this flagellated parasite
56 consists of two evolutionary stages: i) the trophozoite, which adheres to the intestinal
57 epithelium and multiplies by binary fission, and ii) the infectious stage, the cyst,  that is
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58 released through feces and is  acquired by ingestion of food or water. Giardia has a
59 simple cell biology, lacking organelles and a typical endosomal sorting complex required
60 for transport, the ESCRT (Saha et al., 2018). The parasite access nutrients trough
61 specialized structures called peripheral vesicles (PV), and the secretion of cyst wall
62 proteins is operated by the encystation-specific vesicles (ESVs) which are absent in non-
63 encysting trophozoites (Gottig et al., 2006).The virulence factors involved in Giardia
64 pathogenesis have been described, including the cysteine proteases, which have been well
65 studied..These are involved in intestinal epithelial junctional complex disruption and
66 degradation of host immune factors, e.g. cytokines. (Cotton et al., 2015; Liu et al., 2018;
67 Bartelt & Sartor, 2015). The parasite is also capable of evading the adaptive immune
68 defense through antigenic variation (Prucca et al., 2008; Serradell et al., 2016). Yet,
69 pathogenesis remains to be fully understood. Finally, chronic infection is a significant
70 concern in giardiasis, as it represents nutritional implications for children and
71 immunocompromised individuals.(Halliez & Buret, 2013; Bartelt & Sartor, 2015).
72 Adaptions of protozoans  for survival in the host involve sophisticated forms of host-
73 pathogen communication (Cipriano & Hajduk, 2018). Importantly, many reports have
74 described the release of extracellular vesicles (EVs) from pathogens to be relevant to
75 disease status (Cwiklinski et al., 2015; Coakley et al., 2017). EVs are found in most
76 biological fluids and are 30-1000 nm lipid-bilayer vesicles, which are shed from cells and
77 transport a range of biomolecules, including protein and genetic material, participating in
78 cell communication in physiological and pathophysiological processes (Coakley et al.,
79 2015; Nawaz et al., 2016; Maas et al., 2017; van Niel et al., 2018; Ramirez et al., 2018;
80 Ryu et al., 2018).
81
82 Our group has previously described EV release of G. intestinalis and established that
83 giardial EVs are involved in host-pathogen interactions via immunomodulation and
84 trophozoite persistence (Evans-Osses et al., 2017). In addition, Ma´ayeh et al (2017)
85 recovered EVs from the secretome of axenic culture. In recent years, there has been a
86 growing interest to improve current knowledge of the nature, constitution and biogenesis
87 of all secreted EVs. In the last decades the term “exosomes” was proposed to refer to
88 smaller EVs (sEVs) of multivesicular bodies origin (<100 nm diameter). Concomitantly,
89 larger EVs (LEVs) called “microvesicles” (~100-1000 nm) are released directly from the
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90 plasma membrane (Tkach et al., 2018; Mathieu et al., 2019). Lately, the field of EVs is
91 debating the need to accurately separate EV subtypes to investigate functional relevance
92 (Tckach et al., 2018). There are current limitations in techniques that analyze EVs and
93 possibly, a relation of size and biological function is an appropriate step towards
94 characterization (Moyano et al., 2019). Enrichment of subpopulations of EVs from
95 samples is acquired based on differential centrifugation steps: large EVs (LEVs) are
96 obtained at speeds lower than 20,000xg and small EVs (SEVs) are pelleted at 100.000xg
97 in a further ultracentrifugation step. Formerly, microvesicles and exosomes, particularly
98 present in LEV and SEV respectively, are considered the main EV subpopulations.
99 Exosomes are the smallest population, continually produced in the late endosome and
100 liberated through the fusion of multivesicular bodies within the plasma membrane.
101 Microvesicles are particles of a larger size produced though a budding from the plasma
102 membrane under stress mediated by scramblase, calpain and Ca2+ liberation (Morrison et
103 al., 2016; Nawaz et al, 2017). Different roles for these EV subpopulations remain a focus
104 of ongoing investigations; are all EVs phenotypically relevant and/or similar?
105 While it is known that EVs are released by multiple mechanisms, some advances in
106 understanding of their biogenesis has been elucidated via studies on the peptidylarginine
107 deiminase (PAD)-mediated pathway of EV release in diverse taxa (Kholia et al., 2015;
108 Kosgodage et al., 2017; Lange et al., 2017; Kosgodage et al., 2018a; Kosgodage et al.,
109 2019a). PADs are phylogenetically conserved enzymes from bacteria to mammals
110 (Vossenaar et al., 2003; Magnadottir et al., 2018; Kosgodage et al., 2019a), including in
111 Giardia (arginine deiminase GiADI; Trejo-Soto et al., 2016). PADs catalyze post-
112 translational deimination by irreversibly changing arginine into citrulline in a calcium-
113 catalyzed manner in target proteins, affecting their folding and function (Vossenaar et al.,
114 2003; György et al., 2006). PADs are involved in pathophysiological processes and their
115 upregulation and associated increase in deiminated proteins is associated with various
116 pathologies including autoimmune and neurodegenerative diseases, as well as cancer
117 (Vossenaar et al., 2003; Wang & Wang 2013; Witalison et al., 2015; Lange et al., 2017;
118 Kosgodage et al., 2018a; Uysal-Onganer et al., 2020). While exact roles for PADs in EV
119 biogenesis and release remain to be fully elucidated, effects on cytoskeletal, nuclear and
120 mitochondrial proteins have been reported (Kholia et al., 2015; Kosgodage et al., 2018a;
121 Uysal-Onganer et al., 2020). As pharmacological PAD-inhibitors have previously been
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122 shown to be potent inhibitors of EV release in various cancer cells and in bacteria, and
123 modulators of EV cargo.(Kholia et al., 2015; Kosgodage et al., 2017; Kosgodage et al.,
124 2018a; Kosgodage et al., 2019a), we sought to investigate a phylogenetically conserved
125 influence of such PAD-inhibitors on the EV production of our parasite model.
126 In addition, cannabidiol (CBD), a phytocannabinoid derived from Cannabis sativa
127 (Mechoulam et al., 2002), was recently identified as a potent EV-inhibitor in cancer cells
128 as well as in bacteria (Kosgodage et al., 2018b, Kosgodage et al., 2019b; Kosgodage et
129 al., 2019c), indicating a phylogenetically conserved function in EV regulation. As
130 cannabinoids have previously been associated with anti-parasitic functions (Nok et al.,
131 1994, Croxford et al., 2005; Roulette et al., 2016) and  reduction of bacterial antibiotic
132 resistance via inhibition of bacterial EVs/MVs (Kosgodage et al., 2019c) we sought to
133 identify whether EV release from Giardia may be affected by CBD, thus elucidating a
134 novel aspect of CBD function on Giardia-host interaction.
135 Here, we report that G. intestinalis produces two populations of EVs that differ in size.
136 The larger EV population had a significant effect on parasite-host adhesion in vitro and
137 was significantly reduced by both PAD-inhibitor and CBD. In addition, treatment with
138 PAD-inhibitor selectively prevented parasite LEV production.
139
140 Methods
141 G. intestinalis isolates and cell culture: G. intestinalis isolate WB (ATCC 50803) were
142 grown in TYI-S-33 medium (Keister, 1983) supplemented with 10% heat-inactivated
143 adult bovine serum with 1% Penicillin/Streptomycin 1000 U (Gibco ™) and  0.5 mg/ml
144 bovine bile (ThermoFisher ™) at 37ºC under microaerophilic conditions. The cultures
145 were maintained in polystyrene tubes (BD Biosciences™ )(13 mL ) until confluence (1 ×
146 106 cells mL). and thereafter sub-cultured, each  for 72 hours. Human colorectal
147 adenocarcinoma cells, Caco-2 cells (ATCC CRL-2102) were cultured in RPMI-1640
148 supplemented with 10% fetal bovine serum, 2mM r-glutamine and 1%
149 Penicillin/Streptomycin 1000 U (Gibco™). Cells were incubated at 37ºC, 5% CO2 until a
150 confluent cell monolayer was reached.
151 EV isolation: For parasite EV isolation, parasites from confluent culture tubes were
152 detached by chilling for 15 min on ice, centrifuged twice (600xg/5min) and the pellets
153 suspended with fresh TYI-S-33 without adult bovine serum (ABS). Parasites were then
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154 counted using a hemocytometer, and diluted to 1x106 per sample according to Evans-
155 Osses et al (2017). Samples were distributed to 1.5 mL microtubes (final volume of 1
156 mL) and 1mM of CaCl2 was added for EV induction and the tubes were then incubated
157 for 1 hour at 37ºC. Then, EV pellets were collected via step-wise centrifugation: first, at
158 600xg/5 min; 4000xg/30 min to eliminate cellular debris, thereafter the supernatant was
159 centrifuged at 15,000xg for 1h and the resulting pellet (LEV) was resuspended in
160 phosphate buffered saline (PBS). The remaining supernatant was then ultracentrifuged
161 for 100,000xg for 4 h, and the resulting EV-containing pellets (SEV) were resuspended
162 in PBS (1x). Both samples were kept at 4°C until further use.
163 For mammalian EV purification, Caco-2 cells were cultured in T25 flasks until
164 confluence, and then the medium was removed. Cultures were washed twice with fresh
165 RPMI-1640 and kept for 1 h with medium omitting ABS, to avoid contamination of EVs
166 from ABS. The supernatant was processed in the same manner as described for the
167 parasite. EVs were stored at 4ºC until further use for host-pathogen interaction assays.
168 EV Quantification and Characterization:  EVs were in the first instance quantified
169 based on their protein concentrations using the Micro BCA assay (ThermoFisher™). For
170 Nanoparticle tracking analysis (NTA, Nanosight, Malvern, U.K.), each sample was
171 diluted 1:100 in PBS (1x) and subjected to a NS300 Nanosight (Malvern™, U.K.), with
172 readings performed in triplicate during 60 s videos at 10 frames per second at room
173 temperature, with the following parameters: camera shutter – 1492, camera gain – 512,
174 detection threshold – 10. The resulting replicate histograms were averaged for
175 presentation in box-plots.
176
177 Treatment of trophozoites with EV-inhibitors: Inoculum of 106 trophozoites per group
178 (triplicates) were stimulated with 1 mM CaCl2 in 1.5 mL microtubes for the production
179 of EVs, with or without EV-inhibitors. Experimental groups were as follows: medium
180 only (control), 100 or 50 μM PAD-inhibitor Cl-amidine (a kind gift from Prof Paul
181 Thompson, UMASS), or with 10 or 5 μM CBD (90899_SIAL, Sigma-Aldrich™). After
182 60 minutes of incubation (37°C), supernatants were processed following the protocol
183 described above for EV isolation.
184 Trophozoites growth curves: A growth curve was generated from the parasites
185 submitted to vesiculation at different time intervals  (1, 3  or 6 hours).
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186  Inoculums of 100 µL at 1x105 trophozoite/mL from  each group were resuspended in a
187 complete TYI-S-33 medium, added to polystyrene culture tubes, and maintained at 37ºC,
188 for an overall time period of 96 hours.Every 24 h, the tubes were chilled on ice for 15
189 min to promote trophozoite detachment, and aliquots of 10 µL were subsequently taken
190 from the culture tubes to count Giardia trophozoites on a hemocytometer under a
191 Bioval optical microscope.
192 Following the protocol described above, we also maintained growth curves from
193 trophozoites treated with Cl-amidine (100 µM), Cannabidiol (CBD) (10 µM) and WT
194 (control).
195
196 Host-pathogen interaction assay exposed to EV-inhibitors: Caco-2 cells were seeded
197 in 24-well plates and grown to 100% confluence. Inoculations of 5x105 trophozoites per
198 group were transferred to the cell monolayer for 3h (37°C) in a final volume of 1 mL /
199 well. The following groups were investigated: medium only (control), 10 μM CBD, 100
200 μM Cl-amidine. After incubation, trophozoite quantification was performed  by
201 centrifuging non-adherent parasites from the supernatant  and counting them from the
202 pellet  using a hematocytometer. The percentage of trophozoites adhering to Caco-2
203 cells was subsequently calculated according to Cotton et al. (2014).
204  Experiments were also conducted with the two different EV populations. In those cases,
205 the co-cultures were treated with 7 or 14 µg LEVs, 7 or 14 µg SEVs. In order to
206 understand whether the EV-modulatory  effect of Cl amidine or CBD was affected by
207 Ca, Mg or IP3 lysozome pathway, we performed an independent experiment where  we
208 treated trophozoites with chelating agents (5mM EDTA or EGTA), and an inhibitor of
209 the PI3K signaling pathway, wortmanin (100nM).We have tried to obtain  preliminary
210 findings  to understand whether there might be a synergism of these agents with either
211 Cl-amidine or CBD inhibitor. As Cl-amidine was the more effective EV inhibitor, we
212 assessed the compounds only in the presence of 100 µM Cl-amidine. In a separate
213 experiment, EVs were subjected to heat inactivation (65ºC/30 min), as described in
214 Salomon et al (2014), and then used as negative controls of EVs to treat trophozoites
215 with or without exposure to Cl-amidine (100 μM).
216  In independent  experiments to assess the effects of mammalian (Caco-2 derived) EVs
217 on trophozoite adhesion, the same host-pathogen interaction assay was used.
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218 Experimental groups were as follows: 7 or 14 µg Caco-2 cell SEVs, 7 or 14 µg Caco-2
219 cell LEVs, and the negative control with medium alone.
220 Influence of protease inhibitor on host-pathogen interaction: the influence of a
221 protease inhibitor was assessed for parasite adhesion to Caco-2 cells. For this, 5x105
222 trophozoites were seeded into Caco-2 cell monolayers  at37ºC. The co-culture
223 wastreated with 1 mM  iodoacetamide (IAA, cysteine protease inhibitor), with or
224 without 3.5 µg LEVs (3 hours), and the negative control with medium alone. Adhesion
225 estimation was performed as in the host-pathogen interaction assay.
226
227 Sample Preparation for Mass-Spectrometry Based-Proteomics EV preparations were
228 resuspended in 8M Urea containing protease inhibitor cocktail (Sigma-Aldrich). Samples
229 were subjected to six cycles of freeze and thaw before being quantified by a fluorometric
230 assay using the Qubit™ Protein Assay Kit (Invitrogen, Carlsbad, CA) platform according
231 to the manufacturer's instructions. A total of ± 100 μg proteins were reduced with
232 10mM Dithiothreitol (DTT) at 30° C for 45 minutes, followed by alkylation of cysteine
233 residues with 40 mM of iodoacetamide (IAA) for 30 minutes at room temperature in the
234 dark. Thereafter, the samples were incubated with DTT 5mM for 15 minutes at 30° C.
235 The samples were digested with trypsin (Promega, Cat#: V5111) (1:50, Enzyme:
236 Substrate) for 18h at 30° C. Following digestion, all reactions were acidified with 10%
237 (v/v) trifluoroacetic acid (1 % v/v final concentration) to stop proteolysis. The samples
238 were centrifuged for 10 minutes at 12,000 x g for 10 minutes to remove insoluble
239 materials. The tryptic peptides were desalted prior to LC-MS analysis using two C18
240 disks (3 M Empore TM C18 extraction disk) stage-tips.
241
242 Nanoflow liquid chromatography coupled to mass spectrometry (nLC-MS/MS)
243 analysis
244 The nLC-MS/MS analysis was performed using an Easy Nano LC1000 (Thermo) HPLC
245 coupled with an LTQ Orbitrap Velos (Thermo), where 10 µL of sample were applied
246 using a 300 nL/min flow rate of Mobile phase A (5% ACN 0.1% formic acid) in a C18
247 EASY-column (2cm x 5 µm x 100 µm; 120 Å pore, Thermo) and separated in a C18
248 PicoFrit PepMap (10 cm x 10 µm x 75 µm; 135 Å pore, New Objective), over 105 min
249 using a linear gradient 2-30% of mobile phase B (100% ACN; 0,1% formic acid). The
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250 eluted peptides were ionized using electrospray. The top 20 most intense precursor-ions
251 with charge-state = 2 were fragmented using CID at 35 normalized collision energy and
252 10 ms activation time. The MS scan range was set between 350-1500 m/z, the MS scan
253 resolution was 60.000, the MS1 ion count was 1x10e6 and the MS2 ion count was
254 3x104. The experiments were analyzed in biological triplicates.
255
256 Protein Identification
257 Raw files were imported to MaxQuant version 1.5.3.8 with Andromeda search machine
258 and searched against Uniprot Giardia intestinalis strain ATCC 50803 WB clone C6
259 database (November 28, 2019 release; 7,156 entries) with 20 ppm for MS/MS. The
260 followed parameters were used: carbamidomethylation of cysteine (57.021464 Da) as a
261 fixed modification, oxidation of methionine (15.994915 Da) and N-terminal acetylation
262 protein (42.010565 Da) were selected as variable modifications. Enzyme specificity was
263 set to full trypsin with maximum of two missed cleavages. The minimum peptide length
264 was set to 7 amino acids.
265
266 EV staining: For uptake assays, EVs were stained and tested with carboxyfluorescein
267 succinimidyl ester (CFSE, ThermoFisherTM), or with the lipophilic dye PKH-26
268 (SigmaAldrich™). For CFSE labelling, 1 µL of the fluorescent dye was diluted with both
269 EV populations in 1 mL PBS. For PKH-26, 2 µL of the fluorescent dye were diluted in 1
270 mL of diluent C and both EV populations were diluted 1/40 in diluent C. Both dilutions
271 were mixed together at a volume ratio of 1:1. For both fluorescent dyes, labelling was
272 continued for 15 min at room temperature in the dark. The reaction was stopped by
273 adding 1 mL Fetum bovine serum, and samples were then washed in PBS (1x), and
274 ultracentrifuged at 15.000xg for 1 h to obtain LEVs and at 100,000xg for 4 h for
275 collection of SEV, as before.
276
277 Parasite EVs uptake by Caco-2 cells: Caco-2 cells were incubated on sterile coverslips
278 at 37?C in 5% CO2 with 7 or 14 μg of PKH26-labeled giardial EVs (ThermoFisher™)
279 for 1h. Caco-2 cell monolayers were also labelled for nuclei (DAPI, blue -
280 ThermoFisher™). After incubation, the cells were washed three times in cold PBS (1x),
281 and fixed with 4 % paraformaldehyde. Coverslips were washed with PBS (1x) and
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282 mounted with 10 μl of a 50 % glycerol solution. Internalized EVs were detected by
283 confocal microscopy (Nikon A1R HD Multifoton Confocal). Images were processed by
284 Image J software (v. 1.48 – open source, Schneider et al., 2012). Fluorescence intensity
285 of two images per sample was obtained in a duplicate experiment, and corrected cellular
286 fluorescence was estimated as in McCloy et al (2014).
287
288 Cytotoxicity Assay of EV-inhibitors toward Caco-2 cells: Caco-2 cells were seeded into
289 a 96-well plate and grown at 37°C in 5% CO2 until confluence in RPMI-1640 medium
290 containing 10% fetal bovine serum and 1% penicillin/streptomycin (10 000 UI). Cells
291 were treated with 10 μM albendazole (ABZ, positive control) , 100 μM Cl-amidine or 10
292 μM CBD,  in a final volume of 100 μL per well. After 48 hours, wells were washed with
293 100 μL of PBS (1x) . Cells were fixed with absolute  methanol (50 μL) for 10 min, after
294 which 50 μL of crystal violet 0.2% in ethanol/water (2% V/V) were added to each tube.
295 After 2 min, the wells were exhaustively washed with 200 μL of PBS (1x). Elution was
296 made with a sodium citrate solution (0.05 μmol, 10 min), and absorbance was
297 determined at 540 nm on a plate spectrophotometer, as described in Missina et al (2018).
298
299 Statistical analysis: Statistical analysis of data was performed with GraphPad Prism 6
300 Software using one or two-way ANOVA test. Values are represented as means ±
301 standard errors of the means (SEM), acquired in biological triplicates. The normality of
302 the data was assessed prior to analysis. P values = 0.05 were defined as significant.
303
304
305 Results
306
307 Giardia EV Biogenesis: identification of two distinct EV populations
308 Two different EV sub-populations were isolated from G. intestinalis. The previous
309 protocol (Evans-Osses et al., 2017) was slightly modified (addition of a 15,000xg step
310 for 1h, increased ultracentrifugation time to 4 hours)  to separate putative large
311 extracellular (LEVs) and small extracellular vesicles (SEVs) from the total EVs
312 described before (Figure 1A). Using this method, LEVs were recovered at 15,000xg and
313 SEVs at 100,000xg. Trophozoites were incubated with calcium chloride, an enhancer of
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314 EV production. This protocol was performed for parasite and mammalian host cells
315 (Caco-2). Nanoparticle tracking analysis (NTA; Figure1B) showed a higher yield of
316 parasite EVs compared with Caco-2 cells (~3 fold higher), as also confirmed by protein
317 detection (Supplementary Figure 1). In addition, Giardia was found to be capable of
318 shedding more LEVs (~ 3 fold higher) compared with SEVs. LEV and SEV fractions
319 showed a respective mean vesicle diameter of 187.6 and 67.7 nm, respectively
320 (Figure1D-E). Growth assessment was performed after stimulating trophozoites to
321 produce EVs for 1, 3 and 6 hours respectively, following the growth curve in a complete
322 medium by 96 h at 37°C, 5% CO2 (Figure 1C),  There were no significant differences
323 observed on the growth-curve from the different groups.
324 PAD-inhibitor and CBD treatment affects Giardia EV biogenesis
325 G. intestinalis trophozoites were treated with PAD-inhibitor Cl-amidine or CBD
326 respectively, to assess the effects on EV release. Both compounds were able to
327 significantly reduce production of EVs from Giardia (Figure 2A). In addition, we
328 assessed the ability to block host-pathogen interactions following treatment with the EV-
329 inhibitors. Indeed, both compounds were capable of decreasing trophozoites adhesion to
330 the Caco-2 cell monolayer (Figure 2B).
331 We further assessed if Cl-amidine affected the release of SEVs and LEVs equally.
332 Concentration of LEVs by NTA estimated a significant difference between treated
333 compared to non-treated groups (~100 fold higher), while there was no difference
334 observed for SEVs between treated versus control non-treated parasites (Figure 2C).
335 The mean diameter (nm) of EVs released in the presence of Cl-amidine was significantly
336 reduced for LEVs as follows:  LEV (245.5), + Cl-am LEV (157.3), SEV (77.2), +Cl-am
337 SEV (99.8). Values of vesicles from each population, as well as ratio particle/ ug protein
338 are shown  in Figure 2D. EVs were exposed to heat inactivation before treatment of co-
339 cultures; Trophozoites treated with Cl-am and EVs showed a higherattachment to Caco-
340 2 cells when compared to parasites treated with Cl-am and heat-inactivated EVs
341 (Supplementary Figure 2).
342  We performed a toxicity test using mammalian cells, and PAD-inhibitor or CBD had no
343 cytotoxic effects at 48 hours post treatment, compared with albenzadole, one of the
344 common drugs used for giardiasis treatment (Figure 2E). Trophozoites exposed to the
345 EV-inhibitors for 1h in the vesiculation protocol were resuspended in culture tubes and
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346 did not show any significant difference in growth-curves, compared with the control
347 culture (Supplementary Figure 3). We furthermore treated trophozoites with chelating
348 agents (EDTA,a Ca2+ /Mg2+ chelator, EGTA,Ca2+ chelator), and WTN (a PI3K inhibitor)
349 in a host-pathogen assay These compounds did not affect parasite adhesion (Figure 2F).
350
351
352 LEVs derived from parasite, but not host EVs, restore the lack of adhesion to host
353 cell of G. intestinalis trophozoites, treated with EV-inhibitors.
354 Due to the identification of the two EV populations, LEVs and SEVs, in G. intestinalis,
355 we sought to verify whether these EV subpopulatinos  had the same phenotype effect on
356 host cell adhesion. For this assay, two concentrations (7 or 14 µg) from both EV
357 populations, corresponding to the EV release for this amount of parasite in in vitro
358 vesiculation, were used. LEVs derived from the parasite were capable of restoring the
359 adherence phenotype following treatment with Cl-amidine, in a dose-dependent manner
360 (Figure 3A). In contrast, no effect was observed in the SEVs treated groups.   These
361 results suggest that physical properties related to adherence can be found in the larger
362 Giardia EVs and therefore, EVs produced by the parasite may selectively influence its
363 phenotype.
364 We next assessed if the EVs  from the host contribute to the adherence process to host
365 cells. Confluent Caco-2 cell monolayers were washed and thereafter treated with Cl-
366 amidine, and trophozoites were added to the wells, followed by treatment with Caco-2
367 cell-derived EVs (Figure 3B). Opposed to what was observed for the trophozoite EVs,
368 neither mammalian LEVs nor SEVs had a phenotypical effect on trophozoite adhesion.
369 Moreover, we sought to investigate the influence of cisteine peptidase  inhibitors on
370 parasite adhesion to Caco-2cells, treated with  IAA..The cysteine protease inhibitor
371 caused a significant reduction in trophozoite adhesion to host cells (Supplementary
372 Figure 4) but this effect was reduced when the parasites were incubated with LEVs from
373 the parasites, indicating that protease activity is not related to the effect on adhesion,
374 observed for EVs.
375
376 EVs subtypes contain different protein profiles
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377 Proteomic analysis of SEVs and LEVs revealed some differences in protein profiles
378 (Supplementary Table 1). A total of 138 quantified proteins were identified in the LEV
379 and SEV groups. Seventy-seven proteins were identified only in the LEV group and 19
380 proteins were exclusively found in the SEVs. Important products related to Giardia
381 genre were found common to both EVs,  including antigenic Variable Surface Proteins
382 (VSPs), giardins, cathepsin B and other virulence factors (arginine deiminase, ornithine
383 carbamoyltransferase).
384 There were 77 proteins exclusively found in LEVs. related to cytoskeleton composition
385 and protein binding (Figure 4 A,B). Products identified in LEV are associated with
386 cytoskeleton, as well as oxidative stress responses, such as Peroxiredoxin-
387 1(Supplementary Table 2). SEVs contained 19 exclusively proteins which some related
388 to ribosome metabolism. Bioinformatic analysis of the Giardia EVs proteome suggests
389 the enrichment of enzymatic and cytoskeletal products, metabolic processes, as well as
390 stress response to oxygen  (Figure 5). Analysis of LEV and SEV specific proteins
391 revealed a distinct cellular sub-localization, such as cytoplasm, nucleus and plasma
392 membrane, while SEVs proteins were mostly cytoplasmic. Protein-protein interaction
393 and gene ontology analysis of LEV and SEV unique proteins revealed different
394 biological processes and different structural domains (Figure 6 A, B, C).
395 Host-pathogen interactions: both SEV and LEV Giardia types are internalized by
396 mammalian cells
397 Giardia derived SEVs and LEVs were analyzed for their ability to interact with host
398 cells. Among the fluorochromes tested for EV labelling, only PKH-26 showed a
399 homogeneous staining. Both PKH26-labelled LEVs and SEVs were incubated with
400 Caco-2 cell monolayers for 1 hour at two concentrations, 7 or 14 µg, respectively.
401 Confocal microscopy revealed punctuated patterns of fluorescence distributed
402 intracellularly in Caco-2 cells (Figure 7A). Both populations appeared to be taken up by
403 the host cells in a dose-dependent manner. Despite LEV intensity internalization being
404 overall observed to be higher, which may relate to larger vesicle size (Figure 7B), final
405 intracellular destiny of the EVs was not determined.
406
407 Discussion
408
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409 The current study describes two distinct EV populations from Giardia intestinalis where
410 large EVs (LEVs), but not small EVs (SEVs), were associated with effective parasite
411 cell adhesion to host intestinal cells (Caco-2) (Figure 3). A role for one of the identified
412 EV populations in host-pathogen interactions was demonstrated, as treatment of G.
413 intestinalis trophozoites with pharmacological EV-inhibitors selectively decreased
414 biogenesis of LEVs (Figure 2). As EV modulatory strategies have been highlighted as an
415 increasingly important approaches in a range of pathologies (Jorfi et al., 2015; Lange et
416 al., 2017; Catalano M, O´Driscoll, 2020; Uysal-Onganer et al., 2020). Therefore, our
417 current findings highlighting such strategies in Giardiasis may be of considerable
418 importance.
419 The pan-PAD-inhibitor Cl-amidine has previously been described as a potent EV-
420 inhibitor, compared to a range of other compounds, in various cancer cells (Kosgodage
421 et al., 2017, Kosgodage et al., 2018a), as well as to affect EV-mediated microRNA
422 export (Kosgodage et al., 2019a; Usyal-Onganer et al., 2020). Studies have also shown
423 that PAD-inhibitors can be strategically used to sensitize cancer cells to chemotherapy
424 (Kholia et al., 2015; Kosgodage et al., 2017) and affect cancer cell invasion (Uysal-
425 Onganer et al., 2020). The effect of PAD-inhibitors on EV release furthermore seems to
426 be a  phylogenetically conserved pathway as PAD-inhibitors were also found to reduce
427 EV release from bacteria and accordingly, to effectively sensitize bacteria to antibiotics
428 (Kosgodage et al., 2019b). The EV-modulatory functions of CBD were also recently
429 revealed, and CBD has even been found to be a more potent EV inhibitor than Cl-
430 amidine in some cancer cell types, also to have chemosensiting effects and showing
431 selective inhibition on smaller or larger EVs according to cancer type (Kosgodage et al.,
432 2018b). Furthermore, CBD was recently revealed to reduce bacterial EV release, modify
433 proteomic content of bacterial EVs and to sensitize certain bacteria to antibiotic
434 treatment via this pathway (Kosgodage et al., 2019c), indicating also a phylogenetically
435 conserved function for CBD in EV modulation. Such EV-modulatory functions, as also
436 observed in our current study in Giardia, may correlate to the reported effects of
437 cannabinoids as anti-parasitic agents, where inhibitory effects on parasite invasion and
438 immunosuppression of trypanosomiasis has been reported (Nok et al., 1994; Croxford et
439 al., 2005). Cannabinoids have furthermore been shown to be effective anti-helmitics
440 (Roulette et al., 2016), while their effects on Giardia have hitherto not been investigated.
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441 Our current findings may therefore be of considerable interest for putative use of CBD in
442 Giardiasis.
443 The field of EV research is still rapidly growing, with characterization of functions of
444 subpopulations gaining increased attention. The complex function of LEVs revealed here
445 in Giardia, suggests that their influence on phenotype could be even more diverse than
446 those of SEVs (Tckach et al, 2018). No biomarkers were considered in the present
447 study, since both EV populations are enriched mixtures of vesicles that fail to contain
448 any unique marker (Kalra et al., 2013; Vader et al., 2016) and parasite cells may have
449 different sets of markers in their genome (Gonçalves et al., 2018; Ramirez et al., 2018).
450 Properties related to different functions of LEV have been studied in non-infectious
451 models. For example, LEVs derived from cancer prostate cells contain substantially
452 more large size ds DNA than SEVs (Vagner et al., 2018). LEVs (microvesicles) derived
453 from platelets were also associated with polymorphonuclear leucocytes increase in
454 adhesion (Fujimi et al., 2002). On the other hand, properties related to cellular adhesion
455 for SEVs isolated from two cancer cell lines have also been identified while the same was
456 not detected for LEVs (Jimenez et al., 2019). LEVs identified in Fasciola hepatica
457 contained protein cargo related to digestion (cathepsin L1 zymogen), while proteomic
458 and functional analyses identified membrane structure components and
459 immunomodulation factors in SEVs (Cwiklinski et al., 2015).
460 EVs from Giardia have previously been studied in host-pathogen interactions. Evans-
461 Osses et al (2017) identified that microvesicles (LEVs) increase in vitro adhesion of
462 trophozoites in Caco-2 cells, and also increase the activation of immature dendritic cells.
463 Moyano et al (2019) characterized a population of SEVs (exosomes), and suggested that
464 EV-release depends of ceramide and Rab11, despite parasite loss of ESCRT machinery.
465 According to Saha et al (2018) the parasite ESCRT is localized at the PV, the
466 endolysosomal equivalent for Giardia. Wampfler et al (2014) conducted a proteomic
467 analysis of specified-PV and ESV content. The latter appears to assume a functional role
468 similar to the endoplasmic reticulum, such as recruitment of ribosomes to organelle
469 membranes (Wampfler et al., 2014). Benchimol et al. (2004) studied the release of ESVs
470 on giardial cell surface. They detected large granules docking in the plasma membrane.
471 In addition, Midlej et al (2019) investigated the release of intraluminal vesicles from
472 trophozoites treated with CaCl2.  Using electron microscopy techniques, they
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473 demonstrated the exocytosis of those vesicles and recovery in the supernatant. In another
474 study, a proteomic analysis of excretory-secretory products (ESP), was conducted,
475 including EVs of axenic cultures and cultures of trophozoite interacting with mammalian
476 cells, identifying proteins related to metabolism, without signal peptides on EVs
477 (Ma’ayeh et al 2017).
478
479 Our proteomic analysis of Giardia EVs detected relevant virulence factors and
480 immunogenic molecules such as cathepsin-B, arginine-metabolizing enzymes and VSPs
481 in both EV subpopulations.. Many proteins found are associated with parasite
482 cytoskeleton, such as giardins, katanin and ankyrin repeat proteins. Due to the prominent
483 role of proteins from cytoskeleton in parasite adhesion and virulence, we propose that
484 Giardia adhesion to epithelial cells could be related to surface molecules and Disk-
485 associated proteins, identified here to be contained in LEVs. These proteins are rich in
486 ankyrin repeats and may contribute to attachment, protein-protein interactions, and
487 stability (Weiland et al., 2005; Andersson et al., 2007; Nosala et al., 2018; Hagen et al.,
488 2020). Some of the giardins detected in LEVs, such as alpha-1 giardin, are capable to
489 bind to glycosaminoglycans present in the intestinal epithelial monolayer, and hence can
490 play a role in the early host–parasite interplay (Weiland et al., 2003).
491
492 Giardia has to survive an unfriendly environment in the small intestine, while it lacks
493 mitochondria and a conventional ROS-scavenging enzyme, such as catalase, superoxide
494 dismutase, and glutathione (GSH) peroxidase. Our proteome analysis also suggests that
495 EVs carry products associated with oxidoreductase activity, such as Peroxiredoxin-1,
496 FixW and PFOR. These products were also identified in the work of Ansell et al (2016).
497 Ma´ayeh et al (2015) investigated the transcriptome of Giardia isolates in oxidative
498 stress (O2, H2O2). Isolate GS revealed higher levels of Peroxiredoxin-1 and other
499 antioxidative products. In another work from the same author (Ma´ayeh et al., 2017), a
500 proteomic analysis of trophozoites incubated with intestinal epithelial cells detected 11
501 proteins with oxidoreductase activity in the WB isolate.
502 Our evidence of dose-dependent internalization of vesicles, together with proteomic data
503 on cytoskeleton protein enrichment, suggests that EVs may be associated with the
I r vi
ew
504 recovery of trophozoite adhesion capacity altered with PAD-inhibitor. Experiments with
505 overexpression of genes in trophozoites, to be released by vesicles as blockage with
506 monoclonal antibodies, could give an idea if the type of interaction is specific and assess
507 downstream effect on molecular EV-cargo. Understanding the internalization and
508 intracellular destiny of EVs and EV subpopulations is a future challenge for further in-
509 depth studies.
510 While the majority of Giardia infected individuals are asymptomatic, giardiasis is a major
511 contributor to malnutrition and growth impairment in children from developing countries
512 (Fink & Singer, 2017). Additionally, the disease may also last for a long term as a
513 chronic infection. Therefore, it is important to identify and study novel clinical strategies
514 that can lead to host recovery. PAD-inhibitor Cl-amidine and CBD were here shown to
515 effectively decrease parasitic EV release, which contributes to parasite adherence into
516 intestinal epithelial cells (Caco 2 cells). They may therefore pose as novel therapeutic
517 candidate agents for cases of chronic giardiasis.
518
519
520 Conclusion
521 Our results suggest that the two EV populations identified in G. intestinalis so far, LEVs
522 and SEVs, have distinct protein content and functions in the phenotype of this pathogen
523 and can be selectively modulated using PAD-inhibitor and CBD (Figure 8). Since
524 adhesion in the epithelial intestine is fundamental to parasite fitness and invasion, and
525 LEVs clearly aid this process, the use of targeted EV–inhibitors, such as Cl-amidine
526 identified here, can be used to selectively interfere with EV secretion, allowing novel
527 treatment strategies in the control of giardiasis.
528
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542 Figure 1. Isolation and characterization of two distinct EV populations produced
543 from Giardia intestinalis. A. The protocol for the isolation of LEVs and SEVs based
544 on differential centrifugation. B. Quantification of vesicle numbers from nanoparticle
545 tracking analysis (NTA). C. Time-course for culture confluence of trophozoite induced
546 to produce EVs for 1, 3 and 6 hours respectively. D-E. Particle size estimated by NTA
547 for LEVs (D) and SEVs (E).  Data are representative of at least three independent
548 experiments and represented as means ± SEM. ##P = 0.01, versus the corresponding
549 group, indicated by line; ns: not significant.
550
551
552
553 Figure 2. EV-inhibitors Cl-amidine and CBD decrease the production of LEVs
554 secreted from G. intestinalis. A. EV protein quantification post-treatment with Cl-
555 amidine (Cl-am; 100 and 50 µM) or CBD (10 and 5 µM). B. Host-pathogen assay
556 concomitant to treatment with PAD-inhibitor (100 µM) or CBD (10 µM). C. Giardia
557 EV concentration estimation by nanoparticle tracking analysis (NTA) post-treatment
558 with 100 µM Cl-am. D. Particle analysis of the parasite distinct EV populations (A, EV
559 size estimation of the distinct EV populations by NTA (nm); B, yield particle/µg of
560 protein obtained in 1x106 cells). E. Cytotoxic effects of the EV-inhibitors on Caco-2 cell
561 monolayers. Cells were incubated for 48 h with ABZ, Cl-am and CBD at 10, 100, and 10
562 μM respectively, or with culture medium. Cell viability was determined by the crystal
563 violet method. F. Effect of Cl-amidin in host-pathogen assay after treatment with EDTA
564 (5 mM), EGTA (5 mM) and wortmannin (WTN; 100 nM).  Data are representative of at
565 least three independent experiments and represented as means ± SEM. **P =  0.01, ***
566 P =  0.001 compared to control group (CTL). #P =  0.05, ##P =  0.01, ###P =  0.001;
567 versus the corresponding group, indicated by line.
568
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569
570 Figure 3. Parasite derived EVs are selectively involved with Giardia adhesion to
571 host cells. A. Adhesion assay following treatment with distinct parasite EV populations
572 and 100 µM Cl-amidine. B. Host-pathogen assay after treatment of Caco-2 cell
573 monolayer with Cl-amidine and incubation with mammalian cell derived EVs. Data are
574 representative of at least three independent experiments and represented as means ±
575 SEM. *P =  0.05, **P =   0.01; compared to control group (CTL). #P =  0.05, ##P = 
576 0.01; versus the corresponding group, indicated by line.
577
578 Figure 4. EV subtypes derived from G. intestinalis differ in protein cargo. A. Venn
579 diagram of peptides identified in LEV and SEV. B. Gene ontology for proteins identified
580 in LEV and SEV.
581
582 Figure 5. Bioinformatic analysis of SEV and LEV proteins. A. Protein-protein
583 interaction networks.  B. Gene ontology. C. Enriched metabolic pathways. D. Pfam
584 domains identified in the total SEV and LEV protein datasets.
585
586 Figure 6.  Protein-protein interaction, biological processes and Pfam domains
587 related to SEV and LEV exclusive proteins. Orange and purple colour indicates
588 exclusive proteins identified in LEV and SEV, respectively. A. Protein-protein
589 interactions between the exclusive proteins of LEV and SEV. B-C. Biological processes
590 and Pfam enriched domains are shown, respectively.
591
592
593 Figure 7. The two G. intestinalis EV sub-populations are efficiently taken up by
594 Caco-2 cells. A. Caco-2 cells incubated with PKH26-labelled LEVs or SEVs. B.
595 Internalized EVs were quantified by means of fluorescence intensity. Background signal
596 was subtracted for every single image before obtaining the fluorescence intensity
597 (Arbitrary Units); scale bars are indicated at 16 µm. Data are representative of at least
598 three independent experiments and represented as means ± SEM. #P =  0.05, ##P = 
599 0.01; versus the corresponding group, indicated by line.
600
601
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602
603 Figure 8. G. intestinalis EV sub-populations have different protein content, and
604 differentially restore adhesion of trophozoites following  EV-inhibitor treatment.
605
606 Supplementary Figure 1. EV Protein estimation from parasite and mammalian
607 cells (Caco-2).  Data are representative of at least three independent experiments and
608 represented as means ± SEM. #, P =  0.05; versus the corresponding group, indicated by
609 line.
610
611
612 Supplementary Figure 2. Host-pathogen assay after treatment with PAD-inhibitors
613 and EVs subjected to heat inactivation. . Data are representative of at least three
614 independent experiments and represented as means ± SEM. #, P =  0.05; versus the
615 corresponding group, indicated by line. *** P =   0.001; compared to control group
616 (CTL).
617
618 Supplementary Figure 3. Growth curve for culture confluence of trophozoite after
619 exposure to 100 µM Cl-am or 10 µM CBD, following 96-hour incubation. Data are
620 representative of at least three independent experiments and represented as means ±
621 SEM. ns: not significant.
622
623 Supplementary Figure 4. Host-pathogen assay treated with a protease inhibitor
624 and LEVs.  Data are representative of at least three independent experiments and
625 represented as means ± SEM. #, P =  0.05; versus the corresponding group, indicated by
626 line. **P =  0.01; compared to control group (CTL).
627
628 Supplementary Table 1. Proteomic content in SEVs and LEVs.
629
630 Supplementary Table 2. Products associated with cytoskeleton (microtubules),
631 ventral disk, median body and flagella and oxidative stress responses found in
632 LEVs.
633
634
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